JP7895922B2 - 抗aベータ抗体 - Google Patents
抗aベータ抗体Info
- Publication number
- JP7895922B2 JP7895922B2 JP2023504285A JP2023504285A JP7895922B2 JP 7895922 B2 JP7895922 B2 JP 7895922B2 JP 2023504285 A JP2023504285 A JP 2023504285A JP 2023504285 A JP2023504285 A JP 2023504285A JP 7895922 B2 JP7895922 B2 JP 7895922B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- disease
- antigen
- binding fragment
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055813P | 2020-07-23 | 2020-07-23 | |
| US63/055,813 | 2020-07-23 | ||
| US202063086589P | 2020-10-01 | 2020-10-01 | |
| US63/086,589 | 2020-10-01 | ||
| US202163187379P | 2021-05-11 | 2021-05-11 | |
| US63/187,379 | 2021-05-11 | ||
| US202163219611P | 2021-07-08 | 2021-07-08 | |
| US63/219,611 | 2021-07-08 | ||
| PCT/US2021/042900 WO2022020680A1 (en) | 2020-07-23 | 2021-07-23 | Anti-abeta antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535024A JP2023535024A (ja) | 2023-08-15 |
| JP2023535024A5 JP2023535024A5 (cg-RX-API-DMAC7.html) | 2024-10-15 |
| JP7895922B2 true JP7895922B2 (ja) | 2026-07-28 |
Family
ID=79728984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504285A Active JP7895922B2 (ja) | 2020-07-23 | 2021-07-23 | 抗aベータ抗体 |
Country Status (16)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021310926A1 (en) | 2020-07-23 | 2023-03-23 | Othair Prothena Limited | Anti-abeta antibodies |
| CN120513256B (zh) * | 2023-01-20 | 2026-07-10 | 迈威(美国)生物治疗有限公司 | 抗淀粉样蛋白β原纤丝/低聚物抗体和其用途 |
| TW202434629A (zh) * | 2023-01-26 | 2024-09-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 以抗類澱粉β (ABETA)抗體治療神經病症之方法 |
| KR20260049797A (ko) * | 2023-07-12 | 2026-04-14 | 로이드 트란 | 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법 |
| AU2025206067A1 (en) * | 2024-01-05 | 2026-07-23 | Othair Prothena Limited | Methods of treating neurological disorders with anti-abeta antibodies |
| WO2026122407A1 (en) * | 2024-12-04 | 2026-06-11 | Merck Sharp & Dohme Llc | Amyloid beta binder, and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003517461A (ja) | 1999-05-28 | 2003-05-27 | ニユーララブ・リミテツド | アミロイド形成疾患の予防および処置 |
| JP2010534650A (ja) | 2007-07-27 | 2010-11-11 | ヤンセン アルツハイマー イミュノセラピー | アミロイド原性疾患の処置 |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3003097A (en) | 1958-07-17 | 1961-10-03 | Gen Electric | Sequence control system for timing motor |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6518011B1 (en) | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| US7629311B2 (en) | 1999-02-24 | 2009-12-08 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| EA006606B1 (ru) | 2000-02-24 | 2006-02-24 | Вашингтон Юниверсити | Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| AU2002258808A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| CA2520853A1 (en) | 2003-03-28 | 2005-03-31 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| WO2005012877A2 (en) | 2003-08-01 | 2005-02-10 | Dna Twopointo Inc. | Systems and methods for antibody engineering |
| US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| WO2005018424A2 (en) | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| AU2005290250A1 (en) | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| EA200700751A1 (ru) | 2004-10-05 | 2008-06-30 | Элан Фарма Интернэшнл Лимитед | Способы и композиции для улучшения продуцирования рекомбинантного белка |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| US20060257396A1 (en) | 2004-12-15 | 2006-11-16 | Jacobsen Jack S | Abeta antibodies for use in improving cognition |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| BRPI0611600B8 (pt) | 2005-06-17 | 2021-05-25 | Wyeth Corp | método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| CA2632828C (en) | 2005-12-12 | 2012-07-10 | F. Hoffmann-La Roche Ag | Antibodies against amyloid beta with glycosylation in the variable region |
| KR101263294B1 (ko) | 2006-03-30 | 2013-06-04 | 글락소 그룹 리미티드 | 아밀로이드베타 펩티드에 대한 항체 |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| RU2498999C2 (ru) | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| WO2008030251A1 (en) | 2006-09-08 | 2008-03-13 | Georgetown University | Deglycosylated anti-amyloid beta antibodies |
| HUE033466T2 (en) | 2006-10-02 | 2017-12-28 | Ac Immune Sa | Humanized antibody to beta-amyloid |
| HUE033325T2 (en) | 2007-01-05 | 2017-11-28 | Univ Zuerich | Anti-beta-amyloid binder antibodies and their use |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| WO2008131298A2 (en) | 2007-04-18 | 2008-10-30 | Elan Pharma International Limited | Prevention and treatment of cerebral amyloid angiopathy |
| HRP20150086T1 (xx) | 2007-06-12 | 2015-02-27 | Ac Immune S.A. | Humanizirana antitijela za beta amiloid |
| AU2008311366B2 (en) | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20100291071A1 (en) | 2008-08-01 | 2010-11-18 | Immunas Pharma, Inc. | Antibody Specific Binding to A-Beta Oligomer and the Use |
| KR20100115340A (ko) | 2007-10-19 | 2010-10-27 | 이무나스 파마 가부시키가이샤 | Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용 |
| AU2008322523B2 (en) | 2007-11-16 | 2013-10-10 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| PL2246427T3 (pl) | 2008-02-08 | 2017-06-30 | Immunas Pharma, Inc. | Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie |
| KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
| US8126653B2 (en) | 2008-07-31 | 2012-02-28 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| WO2010004434A2 (en) | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
| WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| JP5812418B2 (ja) | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Aβオリゴマーに特異的に結合する抗体およびその利用 |
| US8512677B2 (en) | 2009-04-27 | 2013-08-20 | Case Western Reserve University | Pyro-glutamate Aβ targeting agents |
| BRPI1012195A2 (en) | 2009-05-01 | 2018-04-24 | Abbott Laboratories | double variable domain immunoglobulins and their uses |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| WO2011016238A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| WO2011031720A1 (en) | 2009-09-11 | 2011-03-17 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Bispecific nanobodies as a therapeutic for alzheimer's disease |
| PH12012501744A1 (en) | 2010-03-03 | 2021-08-09 | Boehringer Ingelheim Int | Biparatopic abeta binding polypeptides |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9320793B2 (en) | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| SI3339323T1 (sl) | 2010-08-12 | 2019-12-31 | Eli Lilly And Company | Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe |
| WO2012021475A2 (en) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US9534016B2 (en) | 2011-11-28 | 2017-01-03 | Buck Institute For Research On Aging | Netrin loop peptide mimetics and uses thereof |
| EP2807188B1 (en) * | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| ITRM20120383A1 (it) | 2012-03-20 | 2013-09-21 | Uni Degli Studi Di Milano B Icocca | Metodo e kit per la rivelazione di anticorpi. |
| AU2013287119A1 (en) | 2012-07-03 | 2015-01-22 | Janssen Alzheimer Immunotherapy | C-terminal and central epitope a-beta antibodies |
| EP2928494A4 (en) | 2012-12-07 | 2016-11-02 | Biogen Internat Neuroscience Gmbh | METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES |
| US20140314741A1 (en) * | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
| US9486559B2 (en) | 2013-05-07 | 2016-11-08 | Abbott Cardiovascular Systems Inc. | Methods of treatment with a bioresorbable scaffold for neurologic drug delivery |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US20160355573A1 (en) | 2013-09-05 | 2016-12-08 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
| PE20161093A1 (es) * | 2013-12-20 | 2016-10-23 | Neurimmune Holding Ag | Terapia basada en anticuerpos de amiloidosis por transtiretina (ttr) y anticuerpos derivados de humanos de la misma |
| TW202239429A (zh) | 2014-02-08 | 2022-10-16 | 美商建南德克公司 | 治療阿茲海默症之方法 |
| US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| WO2015172837A1 (en) | 2014-05-16 | 2015-11-19 | Universitat Autonoma De Barcelona | SINGLE CHAIN VARIABLE FRAGMENT (scFv) ELONGATION MUTANTS |
| WO2015191934A2 (en) * | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| CN106661103B (zh) | 2014-07-10 | 2020-11-03 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
| EP3174898A2 (en) | 2014-07-29 | 2017-06-07 | Neurimmune Holding AG | Human-derived anti-huntingtin (htt) antibodies and uses thereof |
| WO2016040903A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded amyloid beta protein |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| US20170363645A1 (en) | 2014-12-19 | 2017-12-21 | Probiodrug Ag | Novel Method for the Detection of pGlu-Abeta Peptides |
| US10494425B2 (en) | 2015-02-24 | 2019-12-03 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| NZ739181A (en) | 2015-07-16 | 2023-05-26 | Vivoryon Therapeutics N V | Anti-pyroglutamated amyloid beta humanized antibodies |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| EP3405489A1 (en) | 2016-01-20 | 2018-11-28 | Genentech, Inc. | High dose treatments for alzheimer's disease |
| PL3430397T3 (pl) | 2016-03-14 | 2022-04-04 | Biogen International Neuroscience Gmbh | Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek |
| US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| MX2018015022A (es) | 2016-06-07 | 2019-08-14 | Biogen Int Neuroscience Gmbh | Métodos para el tratamiento de la enfermedad de alzheimer. |
| EP3487531A4 (en) | 2016-07-19 | 2020-03-25 | Annexon, Inc. | TREATMENT OF FRONTO-TEMPORAL DEMENTIA |
| KR102630042B1 (ko) | 2016-10-27 | 2024-01-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물 |
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白-β之抗體及其用途 |
| RU2019114679A (ru) | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| WO2018119001A1 (en) | 2016-12-19 | 2018-06-28 | Fred Hutchinson Cancer Research Center | Peptide-antibody compositions and methods of use thereof |
| EP3354278A1 (en) | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| WO2018204408A1 (en) | 2017-05-02 | 2018-11-08 | Sanford Burnham Prebys Medical Discovery Institute | Methods of diagnosing and treating alzheimer's disease |
| EP3431496A1 (en) | 2017-07-19 | 2019-01-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti- isoasp7 amyloid beta antibodies and uses thereof |
| MD3672631T3 (ro) | 2017-08-22 | 2023-09-30 | Biogen Ma Inc | Compoziții farmaceutice conținând anticorpi anti-beta amiloidici |
| CA3076313A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
| US20190153102A1 (en) | 2017-09-28 | 2019-05-23 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
| US20200330592A1 (en) | 2017-10-09 | 2020-10-22 | Keith Black | Compositions and methods of treating alzheimer's and other amyloid related diseases |
| US12344662B2 (en) | 2018-02-09 | 2025-07-01 | The Trustees Of Dartmouth College | Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders |
| WO2020015637A1 (zh) | 2018-07-17 | 2020-01-23 | 江苏恒瑞医药股份有限公司 | 抗Abeta抗体、其抗原结合片段及应用 |
| WO2020023530A2 (en) | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| US12259395B2 (en) | 2018-08-17 | 2025-03-25 | Ab Studio Inc. | Catabodies and methods of use thereof |
| MX2021004819A (es) | 2018-11-02 | 2021-06-08 | Annexon Inc | Composiciones y metodos para tratar lesiones cerebrales. |
| CA3129890A1 (en) | 2019-02-12 | 2020-08-20 | Prothena Biosciences Limited | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells |
| SG11202110504XA (en) | 2019-03-26 | 2021-10-28 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| EP4010367A4 (en) | 2019-04-04 | 2023-10-11 | The Royal Institution for the Advancement of Learning / McGill University | Use of ass34 to assess alzheimer's disease progression |
| WO2020257745A1 (en) | 2019-06-21 | 2020-12-24 | University Of Kansas | Compositions and methods useful in treating brain diseases |
| ES2821599A1 (es) | 2019-10-24 | 2021-04-26 | Univ Del Pais Vasco / Euskal Herriko Unibertsitatea | Compuestos y metodos para el tratamiento de la enfermedad de alzheimer |
| JP2023506450A (ja) | 2019-12-11 | 2023-02-16 | アンベテックス ピーティーワイ エルティーディー | 拡張機能障害の防止及び治療のためのアミロイドベータ抗体又はワクチンを含む療法組成物 |
| PT4121007T (pt) | 2020-03-20 | 2025-09-25 | Eisai R&D Man Co Ltd | Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas |
| AU2021310926A1 (en) | 2020-07-23 | 2023-03-23 | Othair Prothena Limited | Anti-abeta antibodies |
-
2021
- 2021-07-23 AU AU2021310926A patent/AU2021310926A1/en active Pending
- 2021-07-23 US US17/383,765 patent/US12435129B2/en active Active
- 2021-07-23 UY UY0001039337A patent/UY39337A/es unknown
- 2021-07-23 EP EP21847155.5A patent/EP4185612A4/en active Pending
- 2021-07-23 PH PH1/2023/550178A patent/PH12023550178A1/en unknown
- 2021-07-23 JP JP2023504285A patent/JP7895922B2/ja active Active
- 2021-07-23 CN CN202180063472.XA patent/CN116348487A/zh active Pending
- 2021-07-23 IL IL300059A patent/IL300059A/en unknown
- 2021-07-23 WO PCT/US2021/042900 patent/WO2022020680A1/en not_active Ceased
- 2021-07-23 CA CA3186614A patent/CA3186614A1/en active Pending
- 2021-07-23 MX MX2023000949A patent/MX2023000949A/es unknown
- 2021-07-23 BR BR112023001061A patent/BR112023001061A2/pt unknown
- 2021-07-23 PY PY202102160662A patent/PY2160662A/es unknown
- 2021-07-23 KR KR1020237005881A patent/KR20230039734A/ko active Pending
- 2021-10-25 US US17/510,140 patent/US11434283B2/en active Active
- 2021-10-25 US US17/510,150 patent/US11434284B2/en active Active
- 2021-10-25 US US17/510,160 patent/US20220089762A1/en not_active Abandoned
- 2021-10-25 US US17/510,170 patent/US11434285B2/en active Active
-
2022
- 2022-04-20 US US17/725,363 patent/US11440953B2/en active Active
- 2022-09-12 US US17/931,386 patent/US20230331828A1/en not_active Abandoned
-
2023
- 2023-01-23 CL CL2023000216A patent/CL2023000216A1/es unknown
- 2023-01-23 JO JOJO/P/2023/0017A patent/JOP20230017A1/ar unknown
-
2024
- 2024-04-01 CL CL2024000953A patent/CL2024000953A1/es unknown
- 2024-12-05 US US18/970,569 patent/US20250179161A1/en active Pending
-
2025
- 2025-01-10 CL CL2025000063A patent/CL2025000063A1/es unknown
- 2025-09-04 US US19/319,365 patent/US20260078176A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003517461A (ja) | 1999-05-28 | 2003-05-27 | ニユーララブ・リミテツド | アミロイド形成疾患の予防および処置 |
| JP2010534650A (ja) | 2007-07-27 | 2010-11-11 | ヤンセン アルツハイマー イミュノセラピー | アミロイド原性疾患の処置 |
Non-Patent Citations (1)
| Title |
|---|
| PNAS,1982年,Vol.79,p.1979-1983 |
Also Published As
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230324 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240722 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240722 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241004 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250808 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260612 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260617 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260715 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7895922 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |